Source comparison
Administration Routes and Stability Comparison
BPC-157’s triple-proline conformational rigidity makes it orally active in preclinical models — intragastric (gavage) administration produces approximately 85–90% of the wound healing efficacy of equivalent parenteral doses in matched animal models. This is ex
This comparison does not assign a generated winner or score.
- BPC-157’s triple-proline conformational rigidity makes it orally active in preclinical models — intragastric (gavage) administration produces approximately 85–90% of the wound healing efficacy of equivalent parenteral doses in matched animal models. This is exceptional for a peptide and makes it practically useful in oral administration research designs. For GI-specific models, oral administration may actually provide higher local mucosal concentration than systemic parenteral dosing.
- TB-500, as a larger 43-amino-acid peptide, is subject to typical pepsin and protease degradation in the gut and is not reliably orally active. Subcutaneous, intraperitoneal, and intravenous routes are standard for TB-500 research protocols. For any model where oral administration is experimentally required or preferred (e.g., to eliminate injection stress confounds in anxiety or behavioural models), BPC-157 has a clear practical advantage.
- Storage is equivalent: both are lyophilised powders stored at −20°C long-term, stable at 2–8°C for up to 3 months once received. Reconstitution with bacteriostatic water, swirl gently (no vortex), and use reconstituted peptide within 28 days. For detailed protocols: TB-500 Dosing and Reconstitution Reference.